ABSTRACT
Se detectó la presencia de fluoroquinolonas en varios alimentos (huevos, alimentos para aves y pechuga de pollo), así como determinar el perfil de susceptibilidad de ácido nalidíxico y ciprofloxacina de las enterobacterias aisladas del contenido intestinal de pollos de Cumaná. Se estudiaron alimentos iniciadores y de engorde (de cinco marcas comerciales) y uno para gallinas ponedoras, así como pechugas de pollos nacionales y de Brasil. I-2 y E-1 fueron los que tuvieron las concentraciones más altas de enrofloxacina. El alimento para las gallinas ponedoras (AP 2,35 µg/mg) tuvo más enrofloxacina que los de los pollos. En los huevos, la mayor acumulación se vio en las yemas. Los pollos nacionales (0,43-0,56 µg/mg) acumularon más ciprofloxacina que los pollos de Brasil (0,14 µg/mg). De los hisopados rectales de los pollos, E. coli fue la principal especie aislada. Por antibiograma, 48% de las cepas fueron resistentes a las quinolonas probadas (ácido nalidíxico y ciprofloxacina). Cuando se determinó la concentración mínima inhibitoria a ciprofloxacina, todas las cepas fueron resistentes (8-128 µg/ml). Todos los alimentos muestreados exceden los límites máximos de fluoroquinolonas permitidos en humanos, lo cual ejerce una presión selectiva importante en las bacterias de la microbiota intestinal de los pollos
To detect the presence of fluoroquinolones in several foods (eggs, poultry food and chicken breast), as well as to determine the susceptibility profile of nalidixic acid and ciprofloxacin of strains of enterobacterias from chicken's intestinal content from Cumaná. Starter and fattening foods (of five commercial marks), and one for laying hens, were studied, as well as domestic chicken's breast (and Brazil. I-2 and E-1 were the ones with the highest concentrations of enrofloxacin. The food for laying hens (AP 2,35 µg/mg) had more enrofloxacin than those for chickens. In eggs, greatest accumulation was seen in the yolks. Domestic chickens (0,43-0,56 µg/mg) accumulated more ciprofloxacin than Brazilian ones (0,14 µg/mg). E. coli was the main specie from chicken rectal swabs. By antimicrobial susceptibility testing, 48% were resistant to both quinolones (nalidixic acid and ciprofloxacin). When the minimum inhibitory concentration of ciprofloxacin was determined, all strains were resistant (8-128 µg/ml). All sampled foods exceeded the maximum limits of fluoroquinolones allowed in humans, which puts significant selective pressure on the bacteria in the chicken gut microbiota
ABSTRACT
We developed and validated a stability-indicating assay method for the simultaneous determination of enrofloxacin and piroxicam in combination and in the presence of degradation products. Reverse-phase high-performance liquid chromatography analyses were carried out on a Vertisep C18 column and acetonitrile-water (48:52 v/v, pH 3.0) mobile phase with a 1.00 mL min−1 flow rate. The efficient chromatographic separation of these drugs and their forced degradation products was achieved in less than 5min with a peak purity match factor higher than 950. The method used showed linearity in the concentration ranges of 0.25 to 16.0 µg mL−1 for enrofloxacin (r = 0.9997) and 0.125 to 8.0 µg mL−1 for piroxicam (r = 0.9999) as well as precision (relative standard deviation lower than 2%), accuracy (mean recovery 100 ± 2%), and robustness, according to ICH (International Conference on Harmonization) and AOAC (Association of Official Analytical Chemists) guidelines. This method can simultaneously determine the combination of these drugs in a veterinary formulation and separate the drug peaks from their forced degradation products. Additionally, its optimized chromatographic conditions can contribute to the quality control of this formulation in pharmaceutical manufacturing plants and minimize waste from the organic solvent.
ABSTRACT
Fowls are the main reservoirs of the highly important food-originating pathogen called Campylobacter spp. and broilers' meat and byproducts are the main vehicles of this microorganism. Increasing of Campylobacter spp. resistant strains to fluorquinolones, an antimicrobial class often employed in poultry farming and in human medicine has become a great concern to poultry breeders. In fact, several studies evaluated increasing bacterial resistance against these antimicrobial agents. The role of CmeABC efflux system has been underscored among the resistance mechanisms in Campylobacter spp. to fluorquinolones. This study investigated the occurrence of CmeABC efflux pump in 81 and 78 enrofloxacin resistant strains of Campylobacter jejuni and C. coli respectively, isolated from broilers collected from six abattoirs situated at São José do Vale do Rio Preto/RJ poultry center and from two commercial abattoirs situated at Metropolitan Region of Rio de Janeiro, from 2013 to 2016. The resistance to enrofloxacin was assessed by agar dilution to determine minimum inhibitory concentration (MIC). The CmeABC efflux system was investigated through the detection of genes genes cmeA, cmeB and cmeC by PCR. The activity of CmeABC efflux pump was investigated in 20 strains by using the efflux pump inhibitor Phenylalanine-Arginine ß-Naphthylamide (PAßN). The three genes cmeA, cmeB and cmeC were detected in 94.3% of the strains (C. jejuni = 80 and C. coli = 70), whereas the system was absent or incomplete in 5.7% of strains (C. jejuni = 1 and C. coli = 8). MIC varied between 0.5µg/ml and 64µg/ml, and 88.7% of strains were enrofloxacin resistant and 11.3% featuring intermediate resistance. The inhibition of the efflux pump by PAßN reduced the MIC to enrofloxacin up to eight times in fifteen strains (75%). These results indicate that this system is frequent and active in Campylobacter spp. Resistant strains in the presence of enrofloxacin.(AU)
As aves são os principais reservatórios de Campylobacter spp., importante patógeno de origem alimentar e a carne de frango e produtos derivados são os principais veículos desse microrganismo. O aumento de cepas de Campylobacter spp. resistentes às fluorquinolonas, uma classe antimicrobiana frequentemente empregada na avicultura e na medicina humana, tornou-se uma grande preocupação para os produtores de aves e vários estudos avaliaram o aumento da resistência bacteriana a esses antimicrobianos. O papel do sistema de efluxo CmeABC tem sido enfatizado entre os mecanismos de resistência em Campylobacter spp. à fluorquinolonas. O presente estudo investigou a ocorrência da bomba de efluxo CmeABC em 81 cepas de Campylobacter jejuni e 78 cepas de Campylobacter coli resistentes à enrofloxacina, isoladas de frangos de corte coletados em seis abatedouros situados no polo avícola de São José do Rio Preto/RJ e de dois abatedouros comerciais situados na Região Metropolitana do Rio de Janeiro, de 2013 a 2016. A resistência à enrofloxacina foi avaliada pelo método de diluição em ágar para determinar a concentração inibitória mínima (CIM). O sistema de efluxo CmeABC foi investigado através da detecção dos genes cmeA, cmeB e cmeC por PCR. A atividade da bomba de efluxo CmeABC foi investigada em 20 cepas utilizando o inibidor da bomba de efluxo Phenylalanine-Arginine ß-Naftilamida (PAßN). Os três genes cmeA, cmeB e cmeC foram detectados em 94,3% das cepas (C. jejuni = 80 e C. coli = 70), enquanto o sistema estava ausente ou incompleto em 5,7% das cepas (C. jejuni = 1 e C coli = 8). A CIM variou entre 0,5µg/ml e 64µg/ml e 88,7% das cepas foram resistentes à enrofloxacina, enquanto 11,3% apresentaram resistência intermediária. A inibição da bomba de efluxo pelo PAßN reduziu a CIM da enrofloxacina até oito vezes em quinze cepas (75%). Estes resultados indicam que este sistema é frequente e ativo em cepas resistentes de Campylobacter spp. na presença de enrofloxacina.(AU)
Subject(s)
Animals , Campylobacter/isolation & purification , Microbial Sensitivity Tests/veterinary , Chickens/microbiology , Drug Resistance, Bacterial/physiology , /analysis , BrazilABSTRACT
Enrofloxacin, a fluoroquinolone, is a broad-spectrum antibiotic widely used in veterinary medicine that inhibits the action of bacterial DNA gyrase, resulting in anti-bacterial effects. This study was performed to examine whether enrofloxacin has modulatory and anti-inflammatory activity on immune cells. A few studies have reported the anti-inflammatory effects of enrofloxacin. In this study, we used mouse spleen cells treated with lipopolysaccharide (LPS) and examined the effects of enrofloxacin. Several assays were performed in LPS-treated spleen cells after the enrofloxacin treatment. Enrofloxacin inhibited the metabolic activity and mitochondrial membrane potential of LPS-treated spleen cells significantly. On the other hand, enrofloxacin did not alter the proportion of the subsets in spleen cells, and did not induce cell death. The production of tumor necrosis factor-alpha in LPS-treated spleen cells was inhibited by enrofloxacin. Overall, enrofloxacin had modulatory activity in spleen cells treated with LPS. These data may broaden the use of enrofloxacin as an antibiotic with anti-inflammatory activity in veterinary clinics.
Subject(s)
Animals , Mice , Cell Death , DNA, Bacterial , Hand , Hospitals, Animal , Membrane Potential, Mitochondrial , Spleen , Tumor Necrosis Factor-alpha , Veterinary MedicineABSTRACT
Aim: It has been hypothesized that chondrotoxicity, the main side effect of enrofloxacin use, may be derived from oxidative stress, and this side effect can be confirmed by measuring malondialdehyde and endogen antioxidants following drug application. The primary aim of this research is to determine the effect of enrofloxacin on the joint fluid and blood oxidative status parameters, and it is also to determine the effect on the organ damage parameters. Materials and Methods: In the study, 10 rams received enrofloxacin (10 mg/kg/day, SC) for 14 days. Blood and joint fluids were taken on day 0 (Control) before drug application and 1.5 hours after the last drug application. Plasma and joint fluid malondialdehyde, total antioxidant status, superoxide dismutase, glutathione peroxidase and catalase levels were determined by an ELISA reader. Cardiac (CK-MB mass, troponin I), liver (AST, ALT, ALP, GGT, total protein, albumin) and kidney (Creatinine, BUN) damage markers and hemogram (WBC, RBC, platelet, hematocrit, haemoglobin) values were measured. Results: Enrofloxacin decreased the joint fluid catalase level (P<0.05), while there was no effect observed in the other oxidative status parameters of joint fluid or blood samples. Statistically significant changes (P<0.05) were found in some hemogram and biochemical parameters within the reference range. However, enrofloxacin increased (P<0.05) the levels of cardiac damage markers (CK-MB mass, troponin I). Conclusion: It may be stated that enrofloxacin does not cause oxidative stress in the joint fluid and blood in rams, and it is generally accepted to be safe when the effect on the organ/system is considered, but the long-term use and high doses require caution in terms of possible heart related damage.
ABSTRACT
Pharmacokinetic/pharmacodynamic (PK/PD) ratios of reference enrofloxacin (Enro-R) and enrofloxacin as HCl-2H₂O (Enro-C), as well as Monte Carlo simulations based on composite MIC₅₀ and MIC₉₀ (MIC, minimum inhibitory concentration) vs. Leptospira spp., were carried out in dogs after their intramuscular (IM) or oral administration (10 mg/kg). Plasma determination of enrofloxacin was achieved by means of high-performance liquid chromatography. Maximum plasma concentration values after oral administration were 1.47 ± 0.19 µg/mL and 5.3 ± 0.84 µg/mL for Enro-R and Enro-C, respectively, and 1.6 ± 0.12 µg/mL and 7.6 ± 0.93 µg/mL, respectively, after IM administration. Areas under the plasma vs. time concentration curve in 24 h (AUC₀₋₂₄) were 8.02 µg/mL/h and 36.2 µg/mL/h for Enro-R(oral) and Enro-C(oral), respectively, and 8.55 ± 0.85 µg/mL/h and 56.4 ± 6.21 µg/mL/h after IM administration of Enro-R and Enro-C, respectively. The PK/PD ratios and Monte Carlo simulations obtained with Enro-C, not Enro-R, indicated that its IM administration to dogs will result in therapeutic concentrations appropriate for treating leptospirosis. This is the first time enrofloxacin has been recommended to treat this disease in dogs.
Subject(s)
Animals , Dogs , Administration, Oral , Chromatography, Liquid , Leptospira , Leptospirosis , Pharmacokinetics , PlasmaABSTRACT
The aim of the study was to prepare enrofloxacin nanosuspension injection and evaluate its pharmacokinetics after giving a single intramuscular injection.The high pressure homogeneous technique was used to prepare enrofloxacin nanosuspension injection and preliminary evaluation of the quality was done.The high performance liquid chromatography (HPLC) method was used to determinate content of enrofloxacin in pig plasma.And the pharmacokinetic characteristics of enrofloxacin nanosuspension injection were compared with Baytril injection.The content of enrofloxacin in this preparation is 97.9％.The average particle size of enrofloxacin nanosuspension injection was (613.21±5.78) nm,PDI was (0.22±0.02) and the potential was-2.02 mV.Maximal plasma concentrations were (0.32±0.12) and (0.67 ± 0.09) mg/L after i.m administration with enrofloxacin nanosuspension injection and Baytril injection.The peak times were (2.88 ±0.96) and (0.79±0.26) hours,respectively.Mean elimination half-lifes were (5.99± 1.37) and (4.49 ± 1.25) hours,respectively.Areas under concentration-time curve were (4.63±1.30) and (4.40±0.45) mg/L · h,respectively.Mean residence times were (9.59±2.34) and (5.41±1.10) hours,respectively.The relative bioavailability of enrofloxacin nanosuspension injection was 105.2％.The preparation method of high pressure homogeneous was simple and good reproducibility.Enrofloxacin nanosuspension injection was characterized by non-sedimentation,easy-redispersion,relatively stable.Comparing with Baytril injection,enrofloxacin nanosuspension injection had a certain slowrelease effect,showing slower elimination than enrofloxacin injeetion.
ABSTRACT
Poultry are considered to be the main reservoir of Campylobacterspp. bacteria, an important pathogen for humans. Many studies have reported a rapid selection of fluoroquinolone-resistant strains following the widespread use of these antimicrobials in poultry production and human medicine. The main mechanism of fluoroquinolone resistance in Campylobacteris a mutation in the Quinolone Resistance Determinant Region (QRDR) in the gyrA gene, which codes for the subunit of the enzyme DNA gyrase, the target for fluoroquinolone. The aim of this study was to investigate the mutation in QRDR in the gyrA gene of Campylobacterstrains previously isolated from broiler carcasses and feces of laying hens. Thirty-eight strains of C. jejuniand 19 C. colistrains (n=57), previously characterized as resistant to ciprofloxacin and enrofloxacin by the disk diffusion method and minimum inhibitory concentration (MIC), were selected. For detection of the mutation, a fragment of 454pb QRDR in the gyrA gene was used for direct sequencing. All strains presented the QRDR mutation in the gyrA gene at codon 86 (Thr-86-Ile), which confers resistance to fluoroquinolones. Other known silent mutations were observed. This genotypic characterization of fluoroquinolone resistance inCampylobacterstrains has confirmed the prior phenotypic detection of the resistance. The Thr-86-Ile mutation was observed in all samples confirming that this is the predominant mutation in enrofloxacin and ciprofloxacin resistant strains of C. jejuniand C. coli.
As aves são consideradas o principal reservatório deCampylobacterspp., um importante patógeno para humanos e muitos estudos têm relatado uma rápida seleção de cepas resistentes às fluoroquinolonas após o uso destes antimicrobianos na produção avícola e na medicina humana. O principal mecanismo de resistência às fluoroquinolonas em Campylobacterconsiste na mutação na Região Determinantes de Resistência às Quinolonas (RDRQ) do gene gyrA, que codifica para a subunidade A da enzima DNA girase, alvo das fluoroquinolonas. O objetivo deste estudo foi investigar a mutação na RDRQ do gene gyrA em cepas de Campylobacterpreviamente isolados de carcaças de frangos de corte e fezes de galinhas poedeiras. Foram selecionadas 38 cepas de C. jejunie 19 cepas de C. coli(n=57), previamente caracterizadas como resistentes à ciprofloxacina e enrofloxacina, pelo método da difusão em disco e pela determinação da concentração inibitória mínima. Para detecção da mutação, foi utilizado sequenciamento direto de um fragmento de 454pb da RDRQ do gene gyrA gerado por PCR. Todas as cepas apresentaram a mutação na RDRQ do gene gyrA no códon 86 (Tre-86-Ile), que confere resistência às fluoroquinolonas e outras mutações silenciosas foram observadas. A caracterização genotípica da resistência às fluoroquinolonas em Campylobacterconfirmou a prévia detecção fenotípica dessa resistência e a mutação Tre-86-Ile foi observada na totalidade das amostras, comprovando ser esta a mutação predominante em cepas de C. jejunie C. coliresistentes à enrofloxacina e ciprofloxacina.
ABSTRACT
Monoclonal anti-enrofloxacin antibody was prepared for a direct competitive enzyme-linked immunosorbent assay (ELISA) and purification system using monoclonal antibody (mAb) coupled magnetic nanoparticles (MNPs). The IC50 values of the developed mAb for enrofloxacin (ENR), ciprofloxacin, difloxacin, sarafloxacin, pefloxacin, and norfloxacin were 5.0, 8.3, 9.7, 21.7, 36.0, and 63.7 ng/mL, respectively. The lowest detectable level of ENR was 0.7 ng/mL in the prepared ELISA system. To validate the developed ELISA in the food matrix, known amounts of ENR were spiked in meat and egg samples at 10, 20 and 30 ng/mL. Recoveries for ENR ranged from 72.9 to 113.16% with a coefficient of variation (CV) of 2.42 to 10.11%. The applicability of the mAb-MNP system was verified by testing the recoveries for ENR residue in three different matrices. Recoveries for ENR ranged from 75.16 to 86.36%, while the CV ranged from 5.08 to 11.53%. Overall, ENR-specific monoclonal antibody was prepared and developed for use in competitive to ELISAs for the detection of ENR in animal meat samples. Furthermore, we suggest that a purification system for ENR using mAb-coupled MNPs could be useful for determination of ENR residue in food.
Subject(s)
Animals , Ciprofloxacin , Enzyme-Linked Immunosorbent Assay , Inhibitory Concentration 50 , Meat , Nanoparticles , Norfloxacin , Ovum , PefloxacinABSTRACT
New enrofloxacin microspheres were formulated, and their physical properties, lung-targeting ability, and tissue distribution in rats were examined. The microspheres had a regular and round shape. The mean diameter was 10.06 microm, and the diameter of 89.93% of all microspheres ranged from 7.0 microm to 30.0 microm. Tissue distribution of the microspheres was evaluated along with a conventional enrofloxacin preparation after a single intravenous injection (7.5 mg of enrofloxacin/kg bw). The results showed that the elimination half-life (t(1/2beta)) of enrofloxacin from lung was prolonged from 7.94 h for the conventional enrofloxacin to 13.28 h for the microspheres. Area under the lung concentration versus time curve from 0 h to infinity (AUC(0-infinity)) was increased from 11.66 h.microg/g to 508.00 h.microg/g. The peak concentration (Cmax) in lung was increased from 5.95 microg/g to 93.36 microg/g. Three lung-targeting parameters were further assessed and showed that the microspheres had remarkable lung-targeting capabilities.
Subject(s)
Animals , Female , Humans , Male , Rats , Anti-Bacterial Agents/adverse effects , Drug Delivery Systems/instrumentation , Fluoroquinolones/adverse effects , Half-Life , Injections, Intravenous , Lung/drug effects , Microspheres , Rats, Sprague-Dawley , Tissue DistributionABSTRACT
A enrofloxacina é um dos antimicrobianos mais utilizados na avicultura industrial, e a deposição de resíduos em produtos avícolas, como os ovos, são de grande importância para a saúde pública. Na legislação brasileira não existe padronização do período de carência para o seu uso na produção avícola e não há Limite Máximo de Resíduo (LMR) fixado para enrofloxacina em ovos. Neste estudo, foi utilizado o kit de ELISA comercial (Bioo Scientific(r)) e a LC-MS/MS na pesquisa de enrofloxacina em ovos de 30 galinhas tratadas previamente via água de bebida, com 10mg/kg de enrofloxacina, durante cinco dias. Seis ovos foram coletados diariamente e analisados durante o tratamento e após a sua suspensão, durante 15 dias. A deposição de resíduos obteve níveis máximos no quinto dia de tratamento das aves, declinando gradativamente até não ser detectada a partir do nono dia de suspensão do tratamento. Considerando como base o LMR de 100µg/kg fixado pelo Brasil para tecidos comestíveis de aves e pela União Europeia para músculo, gordura e pele, após seis dias de suspensão do tratamento, os níveis de resíduos foram inferiores a esse limite, tendo como médias 37,43µg/kg na LC-MS/MS e 14,731µg/kg no ELISA. Dentro das condições deste estudo, um período de carência de seis dias seria mais adequado para utilização dos ovos para consumo humano. Foram detectados valores de resíduos nos ovos menores no ELISA em relação à LC-MS/MS para a mesma amostra, mas os dois métodos apresentaram concordância estatística entre si. A LC-MS/MS é o teste recomendado pela legislação brasileira para a análise de resíduos em alimentos; entretanto, pelos resultados obtidos, o kit de ELISA utilizado também pode ser aplicado na detecção de resíduos de enrofloxacina em ovos, com as vantagens de rapidez e simplicidade...
Enrofloxacin is one of the most used antibiotics in the poultry industry and the deposition of residues in poultry products, such as eggs, are of great concern to public health. In Brazilian law there is no standard withdrawal period for enrofloxacin in eggs and there is no Maximum Residue Limit (MRL) established for this antimicrobial in eggs. In this study, (Bioo Scientific(r)) commercial ELISA kit and LC-MS/MS were used to investigate enrofloxacin in eggs of 30 hens pretreated via drinking water at 10mg/kg of enrofloxacin for five days. Six eggs were collected daily and analyzed during treatment and after the end of treatment, for 15 days. Residues obtained maximum levels on the fifth day of treatment, declined gradually and were no longer detected from the ninth day to the end of treatment. Based on the MRL of 100mg/kg established for edible tissues of poultry by Brazillian law and for muscle, fat and skin, by the European Union, after six days of treatment withdrawal, the residue levels were below that limit, with the average of 37.43mg/kg in LC-MS/MS and 14.731mg/kg in ELISA. Within the conditions of this study, a withdrawal period of six days would be more appropriate to use the eggs for human consumption. The values obtained by ELISA for residues in eggs were lower than those obtained in LC-MS/MS for the same sample, however both methods showed statistical agreement. LC-MS/MS is the recommended method by Brazilian legislation for analysis of residues in food, however, according to the results the ELISA kit used can also be applied to the detection of enrofloxacin residues in eggs, with the advantages of speed and simplicity...
Subject(s)
Animals , Eggs/analysis , Eggs/toxicity , Poultry Products/analysis , Poultry Products/toxicity , Agro Toxic Maximum Allowable Limit on Food , PoultryABSTRACT
Estudos têm mostrado efeitos tóxicos da enrofloxacina em diversos tecidos. Assim, testou-se a hipótese de que a enrofloxacina pode interferir no desenvolvimento placentário e gerar efeitos adversos ao feto. A enrofloxacina (Baytril(r)) foi administrada em ratas, na dose de 5mg/kg, diariamente, IM, durante toda a gestação. As placentas foram analisadas morfologicamente, morfometricamente e imuno-histoquimicamente aos sete, 14 e 21 dias de prenhez. Os resultados mostraram que a enrofloxacina reduziu o número de sítios de implantação, o peso e a área total do disco placentário aos 14 e 21 dias de desenvolvimento, além dos elementos constituintes da placenta. A análise histoquímica não revelou alterações significativas no teor de fibras colágenas, elásticas e reticulares. O teste de Tunel mostrou atividade apoptótica apenas nas placentas com 14 dias de desenvolvimento de ambos os grupos, sendo mais intensa no grupo tratado. Não foi observado nenhum indício de malformação na cabeça, no tronco e nos membros dos neonatos. No entanto, houve uma redução significativa no número e no peso dos neonatos no grupo tratado, porém sem afetar o seu comprimento. Assim, concluiu-se que a enrofloxacina administrada na dosagem de 5mg/kg durante prenhez em ratas interfere no número de embriões implantados e no desenvolvimento placentário. Isto sugere cautela na administração da enrofloxacina durante a gestação, pois a exposição contínua a esse antibiótico pode ter reflexos na redução do número e do peso da prole...
Some studies have shown the toxic effects of enrofloxacin in various tissues. Thus, the hypothesis that enrofloxacin could interfere with placental development and generate adverse effects to the fetus was tested in this study. Enrofloxacin (Baytril(r)) was administered in the dose of 5mg/kg daily, i.m., throughout gestation in rats. The placentas were analyzed morphologically, morphometrically, and immunohistochemically on the 7, 14, and 20th days of pregnancy. The results showed that enrofloxacin reduced the number of implantation sites, weight, and placental disk total area at 14 and 20 days of development, in addition to the element components of the placenta. The histochemical analysis did not reveal significant changes in the content of collagen, reticular, and elastic fibers. The TUNEL test showed apoptosis only in placenta development at 14 days in both groups and more intense in the treated group. Head, trunk, and limb malformations were not observed in the neonates. A significant reduction in the number and weight of neonates were observed in the treated group, however, without affecting their length. Thus, it was concluded that the administration of enrofloxacin, at the dosage of 5 mg/kg during pregnancy in rats, interferes in the number of implanted embryos and placental development. This suggests caution in the administration of enrofloxacin during pregnancy because continuous exposure to this antibiotic may have adverse effects, reducing the number and weight of the offspring...
Subject(s)
Animals , Rats , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/adverse effects , Fetus , Placental Function Tests/veterinary , Animals, Newborn , Pregnancy, AnimalABSTRACT
Four groups of six Holstein calves were inoculated with 3.6 × 10(7) erythrocytes parasitized with Anaplasma marginale. The criteria for treatment of calves were increasing A. marginale rickettsemia and 30% reduction of baseline packed cell volume (PCV) of each animal. Group 1 (G1) received 7.5 mg.kg-1 of enrofloxacin in a single dose; Group 2 (G2) 7.5 mg.kg-1 of enrofloxacin twice every three days; Group 3 (G3) 20 mg.kg-1 of long-acting oxytetracycline in a single dose; and Group 4 (G4) a single dose of PBS. Physical examinations, blood smears and PCV were performed daily. On day treatment, G1, G2 and G3 animals had a mean rickettsemia of 17, 23 and 12%, respectively. At 2 days after treatment (DAT) G1 and G2 animals showed a significant reduction of rickettsemia (p < 0.05) compared to G3. G3 animals had high rates of rickettsemia in the first 2 DAT and a slow decrease until stabilization on 9 DAT. The mean PCV in G1 and G2 increased and stabilized after 7 and 8 DAT, respectively. PCV stabilization was achieved in G3 at 13 DAT. Both enrofloxacin and oxytetracycline were effective for the treatment of anaplasmosis, but enrofloxacin was faster reduction of rickettsemia and PCV recuperation (p < 0.05) compared to oxytetracycline.
Quatro grupos de seis bezerros da raça Holandesa foram inoculados com 3,6 × 10(7) eritrócitos parasitados com Anaplasma marginale. Os critérios para o tratamento dos bezerros foram aumento da rickettsemia do A. marginale e redução de 30% do valor basal de volume globular (VG) de cada animal. O Grupo 1 (G1) recebeu 7,5 mg.kg-1 de enrofloxacina em dose única; o Grupo 2 (G2), 7,5 mg.kg-1 de enrofloxacina duas vezes a cada três dias; o Grupo 3 (G3), 20 mg.kg-1 de oxitetraciclina de longa ação em dose única; e o Grupo 4 (G4) uma única dose de PBS. Exames físicos, esfregaço sanguíneo e VG foram realizadas diariamente. No dia do tratamento, os animais G1, G2 e G3 apresentaram rickettsemia média de 17, 23 e 12%, respectivamente. Nos primeiros 2 dias após o tratamento (DAT) os animais do G1 e G2 mostraram uma redução significativa de rickettsemia (p < 0,05) em relação ao G3. Animais do G3 tiveram altas taxas de rickettsemia nos 2 DAT e uma diminuição lenta até à estabilização em 9 de DAT. O VG médio no G1 e G2 aumentou e estabilizou após 7 e 8 DAT, respectivamente. A estabilização do VG do G3 foi aos 13 DAT. A enrofloxacina e a oxitetraciclina foram efetivas no tratamento da anaplasmose, mas a enrofloxacina apresentou redução da rickettsemia e recuperação do VG (p < 0,05) mais rápida em comparação com oxitetraciclina.
Subject(s)
Animals , Cattle , Male , Anaplasmosis/drug therapy , Cattle Diseases/drug therapy , Fluoroquinolones/therapeutic use , Animal ExperimentationABSTRACT
A 3.4 year-old rhesus macaque weighing 4.5 kg, was suffering from anorexia, acute mucous and bloody diarrhea. On physical examination, the monkey showed a loss of activity, hunched posture, abdominal pain, dehydration, mild gingivitis and unclean anus with discharge. Whole blood was collected for the examination of electrolytes, hematology and serum chemistry; fresh stool was also collected for bacterial culture. Blood profiles showed leukocytosis (14.5 K/microL) and neutrophilia (11.0 K/microL) on complete blood cell count and imbalanced electrolytes associated with diarrhea. As a result of bacterial culture, Shigella flexneri was identified through Mac/SS, IMVIC test, TCBS and VITEK II. Based on these results, this monkey was diagnosed as having acute enteritis caused by Shigella flexneri. Treatment was performed with enrofloxacin prior to the isolation of Shigella flexneri to prevent the transmission of disease. Fortunately, mucus and bloody diarrhea did not persist and general conditions fully recovered. Our results show that the use of enrofloxacin is effective in controlling Shigella flexneri infection in newly acquired rhesus monkeys.
Subject(s)
Abdominal Pain , Anal Canal , Anorexia , Blood Cell Count , Dehydration , Diarrhea , Electrolytes , Enteritis , Fluoroquinolones , Gingivitis , Haplorhini , Hematology , Leukocytosis , Macaca mulatta , Mucus , Physical Examination , Posture , Shigella , Shigella flexneri , Stress, PsychologicalABSTRACT
Se presentan las principales características clínicas y paraclínicas de 11 casos de artritis séptica en equinos admitidos en la Clínica de Grandes Animales de la Universidad Nacional de Colombia entre 2000 y 2004. En general, los resultados son similares a los reportados por la literatura en estudios análogos, aunque se encontró una alta presencia de animales jóvenes en este estudio. Las herramientas paraclínicas más útiles para el diagnóstico fueron el recuento celular y el valor de proteína total en el líquido sinovial, en tanto que la ausencia de bacterias en los extendidos citológicos o los cultivos negativos no descartan la entidad. El uso de enrofloxacina sistémica en estos casos se ha mostrado de valor para la eliminación de la infección articular, a pesar de los riesgos teóricos de su uso en pacientes jóvenes. La artritis séptica debe ser considerada en todos los equinos que desarrollen inflamación y claudicación severas de manera súbita.
The main clinical and paraclinical characteristics of 11 cases of septic arthritis in equine patients admitted to the Large Animal Clinic at the Universidad Nacional de Colombia between 2000 and 2004 are presented. In general terms, the results are close to those reported in similar studies, although an elevated presence of young animals was found in this study. The most useful paraclinical tools for the diagnosis were the white blood cell count and the total protein value in the synovial fluid, whereas the absence of bacteria on direct smears or in culture does not rule out infection as a diagnosis. The use of systemic enrofloxacin in these cases was of value for the removal of the infection, although a theoretical concern exists about the effects of this antibiotic in young animals. Septic arthritis should be considered in every equine patient who develops a sudden swelling and lameness, with or without history of contamination.
Subject(s)
Animals , Arthritis, Infectious , Arthritis, Infectious/veterinary , Horses , Synovial FluidABSTRACT
In the experiment, the production of plagues by Bdellovibrio bacteria in solid medium cultivation, the reproduction of Bdellovibrio bacteria in liquid medium cultivation and the attachment of Bdellovibrio bacteria to carrier were observed, which aimed to study the effects of enrofloxacin on the growth and at-tachment ability of Bdellovibrio bacteria BDF-H16. Results indicated that in solid medium cultivation, the production of plagues by Bdellovibrio bacteria BDF-H16 was inhibited by different concentrations (2 ?g/mL, 5 ?g/mL, 10 ?g/mL, 20 ?g/mL, 50 ?g/mL) of enrofloxacin and the inhibitory effects of enrofloxacin became stronger with the increase of the concentration of enrofloxacin. Similarly, in liquid medium cultivation, the reproduction of Bdellovibrio bacteria BDF-H16 was also obviously inhibited by different concentrations ofenrofloxacin and higher concentrations of enrofloxacin such as 10 ?g/mL, 20 ?g/mL, 50 ?g/mL had stronger inhibitory effects on the reproduction of BDF-H16. However, the growth tendency of Bdellovibrio bacteria BDF-H16 was not inhibited in 10 ?g/mL enrofloxacin. Additionally, when zeolite was added, enrofloxacin had also inhibitory effects on the numbers of Bdellovibrio bacteria BDF-H16 attached to zeolite. With the increase of the concentrations of enrofloxacin, the numbers of Bdellovibrio bacteria BDF-H16 attached to zeolite became smaller and smaller. However, the attachment rate of Bdellovibrio bacteria BDF-H16 to zeo-lite became higher under 2 ?g/mL-20 ?g/mL enrofloxacin. The results above showed that enrofloxacin had inhibitory effects on the plague production and reproduction of Bdellovibrio bacteria BDF-H16, but the at-tachment ability of Bdellovibrio bacteria BDF-H16 was strengthened in liquid medium cultivation with 2 ?g/mL-20 ?g/mL enrofloxacin and zeolite, and adding zeolite helped to reduce the adverse effects of en-rofloxacin on Bdellovibrio bacteria BDF-H16.
ABSTRACT
El presente estudio fue conducido para determinar la presencia de residuos de enrofloxacina en los tejidos (músculo e hígado) de pollos beneficiados en cuatro plantas ubicadas en el municipio San Francisco del estado Zulia, Venezuela. Se tomó un pollo directamente de los expendios ubicados en cada planta durante cinco días consecutivos, dando un total de veinte pollos. El análisis de las muestras se realizó a través de cromatografía líquida de alta resolución (HPLC). La presencia de enrofloxacina se encontró por encima de los Límites Máximos de Residuos sugeridos por la FDA, Codex Alimentario y EMEA, al alcanzar los siguientes resultados: 3,5 mg/kg en muslo, 3,81 mg/kg en pechuga y 3,62 mg/kg en hígado, lo cual abre una duda razonable en relación a la salud de los consumidores de pollo. Adicionalmente, se discute sobre la posibilidad de considerar contaminantes o no, a tales niveles de enrofloxacina.
The present study was lead to determine the presence of remainders of enrofloxacine in tissues (muscle and liver) of slaughtered chickens in four plants located in the San Francisco municipality of the Zulia state, Venezuela. A chicken was taken directly from the retail store in each plant during five consecutive days, giving a total of twenty chickens. The analysis of the samples was made through liquid chromatography of high resolution (HPLC). The enrofloxacine presence was over the Limits Maximum suggested of Remainders by FDA, Nourishing Codex and EMEA, when reaching the following results: 3.50 mg/kg in breast, 3.81 mg/kg in leg and 3.62 mg/kg in liver, which let a reasonable doubt in relation to the health of the chicken consumers. Additionally, it is discussed on the possibility of considering polluting agents or not such levels of enrofloxacine.
ABSTRACT
Antimicrobial susceptibility testing was conducted with 6 different spirochetal strains (4 strains of Leptospira spp. and 2 strains of Borrelia burgdorferi) against 3 antimicrobial agents, commonly used in equine and bovine practice. The ranges of MIC and MBC of amoxicillin against Leptospira spp. were 0.05 - 6.25 microgram/ml and 6.25 - 25.0 microgram/ml, respectively. And the ranges of minimal inhibitory concentration (MIC) and minimal bactericidal concentration (MBC) of amoxicillin against B. burgdorferi were 0.05 - 0.39 microgram/ml and 0.20 - 0.78 microgram/ml, respectively. The ranges of MIC and MBC of enrofloxacin against Leptospira spp. were 0.05 - 0.39 microgram/ml and 0.05 - 0.39 microgram/ml, respectively. Two strains of B. burgdorferi were resistant to enrofloxacin at the highest concentration tested for MBC (> or = 100 microgram/ml). Therefore, the potential role of tilmicosin in the treatment of leptospirosis and borreliosis should be further evaluated in animal models to understand whether the in vivo studies will confirm in vitro results. All spirochetal isolates were inhibited (MIC) and were killed (MBC) by tilmicosin at concentrations below the limit of testing (< or = 0.01 microgram/ml).